Phase II study of 90y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma

被引：0

作者：

Fabregas, Jesus C. ^{[1
,2
]}

Hoffman, James E. ^{[2
,3
]}

Koru-Sengul, Tulay ^{[2
,4
]}

Feng, Miao ^{[2
]}

Goodman, Deborah ^{[2
]}

Serafini, Aldo ^{[2
,5
]}

Hosein, Peter J. ^{[2
,3
]}

Stefanovic, Alexandra ^{[2
,3
]}

Rosenblatt, Joseph D. ^{[2
,3
]}

Lossos, Izidore S. ^{[6
]}

机构：

[1] Univ Miami, Div Hematol Oncol, Miami, FL USA

[2] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA

[3] Univ Miami, Dept Med, Div Hematol Oncol, Miami, FL USA

[4] Dept Publ Hlth Sci, Miami, FL USA

[5] Univ Miami, Sch Med, Dept Radiol, Miami, FL USA

[6] Univ Miami, Miami, FL USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Phase II study of 90Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma
Lossos, Izidore S.
Fabregas, Jesus C.
Koru-Sengul, Tulay
Miao, Feng
Goodman, Deborah
Serafini, Aldo N.
Hosein, Peter J.
Stefanovic, Alexandra
Rosenblatt, Joseph D.
Hoffman, James E.
LEUKEMIA & LYMPHOMA, 2015, 56 (06) : 1750 - 1755
[2] Phase II study of mrium-90 ibritumomab tiuxetan (Zevalin) for patients with untreated stage I-II follicular or marginal zone lymphoma
Samaniego, F.
Pro, B.
Nunez, R.
McLaughlin, P.
Fanale, M.
Kwak, L.
Romaguera, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 351 - 351
[3] Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin)
Gregory, SA
SEMINARS IN ONCOLOGY, 2003, 30 (06) : 17 - 22
[4] A phase II trial of FM (oral Fludarabine and Mitoxantrone) chemotherapy followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin) for previously untreated follicular lymphoma (FL) patients.
Zinzani, PL
Tani, M
Stefoni, V
Alinari, L
Marchi, E
Fina, M
Baccarani, M
BLOOD, 2005, 106 (11) : 271B - 271B
[5] A phase II trial of FM (Oral fludarabine and mitoxantrone) chemotherapy followed by yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for previously untreated follicular lymphoma (FL) patients.
Zinzani, Pier Luigi
Pulsoni, Alessandro
Balocco, Manuela
Tani, Monica
Fanti, Stefano
Perrotti, Alessio
Castellucci, Paolo
Zaja, Francesco
Fabbri, Alberto
Zaccaria, Alfonso
Voso, Maria Teresa
Fattori, Pierpaolo
Guardigni, Luciano
Gentilini, Patrizia
Cabras, Maria Giuseppina
De Renzo, Amalia
Rigacci, Luigi
BLOOD, 2006, 108 (11) : 702A - 702A
[6] Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin)
Hernandez, MC
Knox, SJ
SEMINARS IN ONCOLOGY, 2003, 30 (06) : 6 - 10
[7] A phase ii study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL)
Younes, A
Rodriguez, M
Pro, B
McLaughlin, P
Romaguera, J
Hagemeister, F
Wang, M
ANNALS OF ONCOLOGY, 2005, 16 : 96 - 96
[8] A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL).
Oki, Y
Pro, B
Delpassand, E
Ballaster, V
McLaughlin, P
Romaguera, J
Wang, M
Hagemeister, FB
Younes, A
BLOOD, 2004, 104 (11) : 720A - 720A
[9] A phase II trial of CHOP chemotherapy followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma (DLBCL)
Zinzani, PL
Tani, M
Stefoni, V
Alinari, L
Marchi, E
Fina, M
Baccarani, M
BLOOD, 2005, 106 (11) : 271B - 271B
[10] Phase II trial of abbreviated CHOP-Rituximab followed by 90Y ibritumomab tiuxetan (Zevalin) and rituximab in patients with previously-untreated follicular non-Hodgkin lymphoma (NHL).
DeMonaco, NA
Wu, M
Osborn, J
Evans, T
Foon, KA
Swerdlow, SH
Kant, J
Joyce, J
Land, SR
Jacobs, SA
BLOOD, 2005, 106 (11) : 689A - 689A

← 1 2 3 4 5 →